AML typical mutations (CEBPA, FLT3, and NPM1) identify a high-risk CMML independent of CPSS-Mol classification.
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes-González JF, Azaceta G, Ibañez M, Chen-Liang TH, Notario Mc Donnell C, Amer-Salas N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo Moreno JR, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M.
Castaño-Díez S, et al. Among authors: zamora l.
Blood Adv. 2024 Oct 10:bloodadvances.2024013648. doi: 10.1182/bloodadvances.2024013648. Online ahead of print.
Blood Adv. 2024.
PMID: 39388660